ITM, a radiopharmaceutical biotech company, is dedicated to providing the most precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians and our partners through excellence in development, production and global supply. With patient benefit as the driving principle for all we do, ITM is advancing a broad pipeline, including two phase III studies, combining its high-quality radioisotopes with targeting molecules to develop precision oncology treatments. ITM is leveraging its leadership and nearly two decades of radiopharma expertise combined with its worldwide network to enable nuclear medicine to reach its full potential for helping patients live longer and better.

For more information please visit:  www.itm-radiopharma.com



ITM at a glance:

Field of Activity
Precision Medicine, Precision Oncology, Targeted Radionuclide Therapy / PRRT
Products/Services  1.) Development of targeted radiopharmaceuticals for cancer treatment

Our lead candidate ITM-11 (n.c.a. 177Lu-edotreotide) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is currently under investigation in two phase III clinical trials, COMPETE and COMPOSE. ITM-11 is a Targeted Radionuclide Therapeutic consisting of the high-quality radioisotope no-carrier-added lutetium-177 chelated to a somatostatin analogue to specifically target GEP-NETs.

2) Therapeutic & diagnostic radioisotopes

3) Equipment for Radiolabeling & Quality Control: iQS-Theranostics Synthesizer, iQS® Ga-68 Fluidic Labeling ­Module, Consumables (Reagent Sets, Cassettes), Quality Control Solution (radio-HPLC)

4) GMP Radiolabeling Service

Unique Selling Point ITM is an established company with a proven history as a radioisotope manufacturer and supplier and an emerging leader as a radiopharmaceutical company with a strong precision oncology drug development program including two phase III clinical trials. We are leveraging our expertise in drug development, GMP manufacturing, commercialization and global supply logistics for both diagnostic and therapeutic radioisotopes and radiopharmaceuticals to meet the needs of healthcare professionals and their patients across the globe.
Membership in networks/associations

BioM Biotech Cluster Development GmbH, BIO Deutschland e.V., ENETS European Neuroendocrine Tumor Society, INCA International Neuroendocrine Cancer Alliance, The Carcinoid Cancer Foundation, Inc. (Patient Organization)

Date of Incorporation/
Number of Employees



Address Lichtenbergstr. 1
85748 Garching/Munich
Telephone +49 89 329 8986-600
E-Mail info@itm-radiopharma.com
Web Address www.itm-radiopharma.com
Social Media LinkedIn Twitter Facebook